Inactive Instrument

Highlights Fennec Pharmaceuticals Inc Other OTC

Equities

CA31447P1009

Real-time Estimate Cboe BZX Other stock markets 15:28:06 16/05/2024 BST			5-day change	1st Jan Change
6.9 ^USD	-2.54%		+3.66%	+10.97%

05-15	HC Wainwright Adjusts Fennec Pharmaceuticals Price Target to $15 From $18, Maintains Buy Rating	MT
05-14	Transcript : Fennec Pharmaceuticals Inc., Q1 2024 Earnings Call, May 14, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Fennec Pharmaceuticals Swings to Q1 Profit on Higher Sales, Licensing Revenue	05-14	MT
Fennec Pharmaceuticals Brief: Company Says Has Approximately US$51 Million in Cash, Cash Equivalents, and Investment Securities	05-14	MT
Fennec Pharmaceuticals Brief: Achieved Q1 2024 Total Net Revenues of US$25.4 Million, Including $18.0 Million in Licensing Revenue from Recently Announced Norgine Transaction	05-14	MT
Fennec Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Wedbush on Fennec's Q4	03-21	MT
Fennec Pharmaceuticals up 3.2% in US Premarket, Reports Narrower Q4 Loss of $0.10 Per Share	03-21	MT
Fennec Pharmaceuticals Brief: Cited Pro forma fourth quarter cash in excess of US$55 million	03-21	MT
Fennec Pharmaceuticals Brief: Achieved PEDMARK Full-Year 2023 Net Product Sales of US$21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023	03-21	MT
North American Morning Briefing : Investors -2-	03-21	DJ
Fennec Pharmaceuticals Brief: Net losses for the fourth quarter and year ended December 31, 2023, of US$2.7 million ($0.10 per share) and $16.0 million ($0.60 per share), respectively	03-21	MT
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-21	CI
Fennec Pharmaceuticals, Norgine in Exclusive Licensing Agreement to Commercialize Pedmarqsi in Europe, Australia, and NZ	03-18	MT
Fennec Pharmaceuticals Brief: Fennec Pharmaceuticals and Norgine Over the Weekend Entered into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand	03-18	MT
Fennec Pharmaceuticals Inc. and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand	03-18	CI
Fennec Pharmaceuticals Inc. Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2023	02-29	CI
Fennec Pharmaceuticals Brief: Full-year 2023 net revenues are expected to be approximately US$20.7 to $21.2 million	02-29	MT
Fennec Pharmaceuticals Brief: Q4 2023 net revenues are expected to be approximately US$9.2 to $9.7 million, which represents approximately a 41-49% increase over the third quarter of 2023	02-29	MT
Wedbush Maintains Outperform on Fennec Pharmaceuticals	02-01	MT
FDA Issues Reminder of Non-Substitution of Fennec Pharmaceuticals' Pedmark For Pediatric Patients Receiving Cisplatin	02-01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Fennec Pharmaceuticals Inc Other OTC

Equities

CA31447P1009

Highlights

Filters